Candel Therapeutics (CADL) Income from Continuing Operations: 2020-2024
Historic Income from Continuing Operations for Candel Therapeutics (CADL) over the last 5 years, with Dec 2024 value amounting to -$30.2 million.
- Candel Therapeutics' Income from Continuing Operations rose 31.61% to -$5.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$33.7 million, marking a year-over-year increase of 3.54%. This contributed to the annual value of -$30.2 million for FY2024, which is 10.44% up from last year.
- Per Candel Therapeutics' latest filing, its Income from Continuing Operations stood at -$30.2 million for FY2024, which was up 10.44% from -$33.7 million recorded in FY2023.
- Candel Therapeutics' Income from Continuing Operations' 5-year high stood at -$13.7 million during FY2020, with a 5-year trough of -$35.2 million in FY2022.
- Its 3-year average for Income from Continuing Operations is -$33.0 million, with a median of -$33.7 million in 2023.
- In the last 5 years, Candel Therapeutics' Income from Continuing Operations slumped by 88.18% in 2021 and then grew by 10.44% in 2024.
- Yearly analysis of 5 years shows Candel Therapeutics' Income from Continuing Operations stood at -$13.7 million in 2020, then plummeted by 88.18% to -$25.8 million in 2021, then tumbled by 36.59% to -$35.2 million in 2022, then grew by 4.25% to -$33.7 million in 2023, then rose by 10.44% to -$30.2 million in 2024.